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EXPERIENCE of the limitations of cortisone and hydrocortisone as therapeutic
agents in the management of patients with rheumatoid arthritis has led to a search
for newer and more potent compounds with fewer undesirable side effects. With
the knowledge that the physiological properties of the adrenal steroids can be
modified by relatively minor adjustments of their structural formula, a number
of compounds have been synthesised and tried therapeutically. One of the earliest
of these, 9x-fluoro-hydrocortisone acetate was tested by Boland and Headley in
1954, who found its anti-rheumatic activity to be about ten times greater than
that of hydrocortisone, but unfortunately the drug had marked salt and water
retaining properties which prevented its use as a practical method of treatment.
More recently prednisone and prednisolone have been synthesised. These two
drugs are analogues of cortisone and hydrocortisone respectively, are derived from
them, and differ only in having a double bond linkage between the first and second
carbon atoms of the steroid nucleus. Bunim, Pechet, and Bollet (1955) were
the first to describe their successful use in seven cases of rheumatoid arthritis,
and since then further reports have followed confirming the effectiveness of both
drugs (Dordick and Gluck, 1955; Margolis, Barr, Stolzer, Eisenbeis, and Martz,
1955; Hart, Clark, and Golding, 1955; and Boland, 1956). At present the general
opinion held is that both substances possess an anti-rheumatic effect about three
to five times greater than cortisone, and when employed in equivalent therapeutic
dosage they have less sodium-retaining properties (Bunim, Pechet, and Bollet,
1955; and Nabarro, Stewart, and Walker, 1955). There is apparently little, if any,
difference in the two drugs in respect of their usefulness or side effects (Bunim,
Pechet, and Bollet, 1955), and Boland (1955) considered them interchangeable.
From these preliminary observations it seemed that these drugs were capable
of modifying and suppressing rheumatic activity to an extent greater than any
drug hitherto employed in the treatment of rheumatoid arthritis. For these reasons
and because the majority of existing reports had been concerned with the short-
term aspects of treatment, it was decided to carry out an extended trial of
prednisone and prednisolone in a group of patients with severe and incapacitating
rheumatoid arthritis. The object of the study was to discover-
1. The usefulness or otherwise of the drugs as a method of long-term treatment.
2. To evaluate the degree of improvement, objective and subjective, which
could be achieved during treatment.
513. To discover whether long-term treatment would reveal diminishing anti-
rheumatic activity previously observed to occur with cortisone and hydro-
cortisone.
4. To discover and assess the nature and seriousness of side effects during
continued treatment.
METHOD.
Eleven patients with rheumatoid arthritis were treated in hospital and at a
special out-patient clinic. Each was chosen for treatment because of the severity
of the arthritis, or because of the failure of traditional methods to provide reason.
able relief of symptoms. Initially, they were admitted to hospital, where a complete
clinical examination and survey of their joints was made. Preliminary radiographs
of the chest and barium meal examination of the gastro-intestinal tract were
obtained in each case because of the known hazards of adrenal steroid therapy in
reactivating healed pulmonary tuberculosis and producing peptic ulcers. No
patient was treated who had a history of dyspepsia or who was known to have
had a previous peptic ulcer.
Before starting treatment joint function was assessed. This included measurement
of the circumference of the proximal interphalangeal joints (P.I.P.) with jewellers'
rings; the mobility of the major joints, wrists, elbows, knees, and ankles; the
maximum circumference of the knee joints; and the power of the hand grip by
the patient's ability to squeeze an inflated sphygmomanometer cuff above 50 mm.
of mercury. At one, three, six, and twelve months later patients were re-examined
and the degree of improvement recorded as follows
Grip.
Each 10 mm. increase in strength was scored as one point (+ 1). Where a
decrease was observecd a negative sign was recorded.
Proximal Itnterphalatugeal joinit Size..
Each P.I.P. joint was measured. The ring sizes go from A to Z and were
numbered 1 to 26. The total score for the eight joints was recorded and the
percentage increase or decrease noted at each examination.
Joint Mobility.
Each 5 degree increase in joint movement over the initial angle of movement
was scored as one point. Where fibrous or bony ankylosis was present movement
could not be expected to improve so that, in affected patients, only the more mobile
joints were measured. Three patients had their knee-joints manipulated under
anaesthesia while in hospital, but the increased joint mobility obtained was excluded
from the main findings.
Knee-joint Circumference.
The maximum knee-joint circumference was measured in centimetres. Each
half-centimetre (0.5 cm.) decrease in joint size was scored as -2 points. If the
joint size increased a positive sign was recorded.
52The Erythrocyte Sedimentation Rate (E.S.R.).
The Westergren method was adopted and the figures obtained at the ex-
aminations are shown in the results.
Stage and Grade of Arthritis.
This was assessed before treatment started and at the end of six and twelve
months, and the degree of therapeutic response estimated in accordance with the
recommendation of the American Rheumatism Association (Steinbrocker, Traeger,
and Batterman, 1949).
The composition of the series of patients treated is given in Table 1.
TABLE 1.
DURATION
SEX AGE ARTHRITIS STAGE CLASS
PREVIOUS DRUG
THERAPY
1. G.R.
2. M.G.
3. M. S.
4. T. R.
5. B. I.
6. W. A. L. S.
7. G.T.
8. R. J. McV.
9. D. B.
10. L. B.
11. J. M.
... lU 8 montns III Iv Aspirin.
F 41 4 years ... IV ... III Aspirin, gold,
corticotrophin,
cortisone,
phenylbutazone.
F. 38 11 years ... IV ... IV Aspirin, gold,
phenylbutazone.
M... 64 1.ya years ... IV ... II-III Aspirin,
phenylbutazone,
F. 58 14 years ... IV III Aspirin, gold,
pregnenolone,
phenylbutazone.
cortisone.
M. 39 10 years ... IV III Gold, aspirin,
corticotrophin,
cortisone,
phenylbutazone.
M. 45 6 years ... IV ... II-III Aspirin, gold,
pfienylbutazone.
M... 50 5 years IV ... IV Aspirin, gold,
phenylbutazone.
F. 35 14 years ... IV III Aspirin, gold,
codeine.
F. 49 15 years ... IV III Aspirin, codeine,
phenylbutazone.
F. 62 16 years ... IV III Aspirin, gold.
The Stage refers to severity of joint involvement. Stage I early; Stage II moderate;
Stage III severe with cartilage and bone destruction, joint deformity, etc., and extra
articular soft tissue lesions such as nodules. Stage IV includes criteria of Stage III
together with bony or fibrous ankylosis of joints. The Class refers to the patient's
functional capacity. Class I complete functional capacity to carry on usual activities.
Class II capacity adequate to conduct normal activities despite handicap. Class III
functional activity limited. Class IV largely or wholly incapacitated; patient bedridden
or confined to wheel-chair.
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CASE No.
_ --1_ TTTY TIT air .tfl..STEROID THERAPY.
Initially, all patients were given prednisolone, but on occasions prednisone was
used instead, depending on supplies of each drug available in the dispensary.
No differences in the effects of the two were observed, and for the purposes of
this report the term prednisolone covers the use of both drugs. Treatment was
started in each case with a standard amount of 30 mg. daily in four divided doses,
irrespective of the severity or duration of the arthritis. The drug was then
gradually reduced to an effective maintenance level. Usually within twenty-four
hours there was noticeable subjective improvement, pain and stiffness easing, and
the patient felt more cheerful. Objective changes lagged behind subjective
improvement, although a distinct alteration could be recorded within a week or
so of starting treatment. This was particularly noticeable with the return of strength
to the patient's grip, but decreases in joint size and increases in joint movement
took place more slowly and the maximum response was not obtained for several
weeks.
TABLE 2.
NUMBER OF
Length of time on maximum dosage of 30 mg. Prednisolone daily. PATIENTS
(a) More than. 7 days (total 8 days) - - - - 1
(b) Less than 7 days - - - - - 10
Length of time required to achieve maintenance levels.
(a) Under 30 days -- 2
(b) 30-60 days - - - 7
(c) More than 60 days (96 and 88 days), Cases 3 and 7 - 2
Maintenance dose at end of 6 months' treatment.
(a) 7.5 mg. daily - - 2
(b) 10 mg. daily - - 7
(c) 12.5 mg. daily - - - - - - 2
Maintenance dose at end of 12 months' treatment.
(a) 7.5 mg. daily - - 2
(b) 10 mg. daily - - 5
(c) 12.5 mg. daily - - - - - - 3
(d) 15 mg. daily - - 1
(N.B.-Cases 10 and 11 assessed at 11 and 10 months respectively.)
Number of patients who had reactivation of the rheumatoid
process during maintenance treatment and requiring
temporary or permanent increase in prednisolone dosage.
(a) Requiring temporary increase in dosage and able to return
to previous maintenance treatment (Cases 1 and 3) - 2
(b) Requiring temporary increase in dosage and permanent
increase in maintenance treatment (Cases 4, 5, and 7) - 3
54The initial daily dose of prednisolone was continued for five or six days and then
progressively reduced by 2.5 mg. on alternate days until 20 mg. was being given.
It was held at this level for several days before further withdrawals were made.
When the daily dose reached 15 or 12.5 mg. the patients were discharged from
hospital. Treatment was always conservative, for it was decided to reduce the
prednisolone as quickly as possible to lessen the risk of toxic effects, and, since
the trial was primarily concerned with long-term aspects of treatment, general
improvement in symptoms was aimed at and not complete suppression of rheumatoid
activity.
D'uring out-patient supervision the drug was further reduced to levels which
kept the patient comfortable and allowed a resumption of work. Maintenance
treatment varied between 7.5 mg. and 15 mg. a day with the majority of patients
needing 10 mg. or less. In two patients (Cases 3 and 7) initial reduction in therapy
was too rapid, and the recurrence of symptoms necessitated a temporary increase
for a number of weeks before final maintenance treatment could be achieved.
In four other patients symptoms increased when a daily controlling dose of 10 mg.
of prednisolone was reduced to 7.5 mg. in an effort to arrive at the lowest possible
maintenance level. Such symptoms occurring during the phase of prednisolone
reduction were due to unmasking of the underlying rheumatoid process as a
result of too rapid withdrawal of the drug or reducing it below the effective
controlling dose, and were not the result of a real increase in rheumatoid activity.
The occurrence, however, of a true reactivation was seen in five patients when
they were on steady maintenance treatment. In two (Cases 1 and 3) a return to
the original controlling dose was possible after a temporary increase, but in three
others (Cases 4, 5, and 7) re-establishment of control could only be maintained by
increasing the drug to levels higher than those given before reactivation took place.
Details of the treatment employed are given in Table 2.
RESULTS.
Clinical Assessment.
The criteria recommended by the American Rheumatism Association (Stein-
brocker, Traeger, and Batterman, 1949) to classify the severity of the arthritis,
and to express the degree of improvement achieved, were adopted. The patients
were assessed before treatment and at six and twelve months later, and the
results recorded in Table No. 3. No alteration in the stage of the arthritic process
was observed, but, as is well known, this rarely occurs particularly in patients
who have established joint damage of irreversible degree. For the purpose,
therefore, of evaluating clinical improvement, two variables are available for
comparison. Firstly, alteration in functional capacity, and, secondly, improvement
in rheumatoid activity revealed by the grade of response to treatment.
Distinct improvement in functional activity was recorded in each patient at the
end of six months. Two (Cases 1 and 3) improved by two classes and the remainder
by one. At twelve months this improvement was maintained in all patients except
in one (Case 4), where a slight but definite lessening in functional capacity was
noticed. At six months nine patients showed a Grade 2 response to treatment
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CLASSIFICATION OF DISEASE STATE
BEFORE TREATMENT AFTER TREATMENT
Activity of At At
Rheumatic 6 months 12 months
State Stage Class Stage Class Stage Class
THERAPEUTIC RESPONSE
TO TREATMENT
At At
6 months 12 months
1. G. R. ... Active ...3...4...3..2 ... 3 ... 2 ... Grade 2 ... Grade 2
2. M. G. ... Active ... 4 ... 3 ... 4 ... 2 ... 4 ... 2 ... ,, 2 ...,, 2
3. M. S. ... Active ...4 ... 4 ... 4 ... 2 ... 4 2... ,, 2 ...,, 2
4. T. R. ... Active ... 4 ... 2-3 ... 4 ... 2 ... 4 2-3... 2-3 ...,, 4
5. B.I. ... Active ... ... 4 ... 2 ... 4 ... 2 ... 2 ...,, 2
6. W.A. L.S. ... Active ... 4 ... 3 ... 4 ... 2 ... 4 ... 2 ... ,, 2 ... ,, 2
7. G. T. ... Active ... 4 ... 2-3 ... 4 ... 2 ... 4 ... 2 ... ,, 3 ...,, 2
8. R. J. McV. ... Active ... 4 ... 4...4...3 ...4 ... 3 ... ,, 2 ...,, 3
9. D. B. ... Active ... 4 ... 3 ... 4 ... 2 ... 4 ...2.. 2...,, 2
10. L. B. ... Active ... 4 ... 3 ... 4 ... 2 ... 4 ...2.. 2 ... ,, 2
11. J. M. ... Active ... 4... 3 ... 4 ... 2 ... 4 ... 2 ... ,, 2 . ,, 2
Grade 1 therapeutic response indicates complete remission of the disease process.
Grade 2 therapeutic response indicates a major improvement.
Grade 3 therapdutic response indicates a minor improvement.
Grade 4 no improvement or progression of the disease process.
CASE No.
TABLE 4.
INCREASE IN STRENGTH OF HAND GRIP OVER INITIAL READING
(each 10 mm. rise 1 point)-two hands scored together.
Grade of therapeutic
1 month 3 months 6 months 12 months response
at 12 months
1. G. R.
2. M.G.
3. M. S.
4. T. R.
5. B. I.
6. W.A.L.S.
7. G. R.
8. R. J. McV'.
9. D. B.
10. L. B.
11. J. M.
Average all
Patients
+ 30.0
+ 9.0
+ 2.6
+ 19.0
+ 10.1
+ 1.0
+ 7.3
+ 2.0
+ 20.5
0.0
+ 6.0
+ 17.5
+ 8.5
+ 7.2
+ 10.0
+ 10.7
+ 3.6
+ 7.7
+ 3.0
+ 18.0
+ 4.0
+ 10.5
+ 32.5
+ 7.5
+ 7.5
+ 11.0
+ 3.6
+ 2.6
+ 10.3
+ 2.5
+ 10.5
+ 0.5
+ 10.5
+35.0
+ 3.0
+ 6.0
- 2.5
0.0
+ 8.5
+10.8
0.0
+19.0
0.0
+10.5
... + 9.7 ... + 9.1 .. + 9.0 ... + 8.2 ...
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CASE No.
2
2
2
4
3
2
2
3
2
2
2which is classified as a major improvement. In order to attain this grading the
patient must show no signs of rheumatoid activity, with the exception of an
elevated sedimentation rate; show resolution of articular and extra articular int
flammation and reveal no signs of any new rheumatoid process. Minimal joint
swelling and impairment of joint mobility associated with this swelling may,
however, be present. Lesser degrees of improvement constitute a Grade 3 response
or minor improvement which was shown in two patients (Cases 4 and 7). Assessment
TABLE 5.
MEASUREMENT OF FINGER SWELLING WITH JEWELLERS' RINGS
% INCREASE (+) AND DECREASE (-) BOTH HANDS.
Grade of therapeutic
CASE No. 1 month 3 months 6 months 12 months response
at 12 months
1. G. R. ...- 7.0 ...- 2.1 ...- 7.... - 0.5 ... 2
2. M. G. ... -17.8 ... -13.8 ... -19.0 ... -18.0 ... 2
3. M. S. ... - 8.2 ... - 8.2... -11.8 ... -11.7 ... 2
4. T. R. ...-18.1 ...- 8.7... - 9.9 ...- 2.3 ... 4
5. B. I. .. -19.0 -. -19.0 -. -11.0.. - 6.6 ... 3
6. W. A. L.S. ... -11.1 ... -11.0 ... - 4.3 ... - 8.0 ... 2
7. G. T. ... -10.3 ... -12.7 ... -12.1 ... - 9.8 ... 2
8. R. J. McV.... - 6.8... - 1.2... + 1.2... + 5.4 ... 3
9. D. B. ... -13.6 ... -18.1 ... - 9.0... - 2.2 ... 2
10. L. B. ... - 5.5 ... -11.0 ... - 3.6 ...- 7.0 ... 2
Il. J. M. . . 10.9 .... 12.1 -. -12.5 -. -11.5 ..2
Average all
Patients ... -11.6 ... -10.6 ... - 9.0 ... - 6.5a
*One hand only recorded.
at twelve months revealed a slight deterioration, with only eight patients making a
major response, two (Cases 5 and 8) had a minor response, and one (Case 4) a
Grade 4 response.
It is difficult to convey through these symbols what the figures actually meant
to the patients in terms of improvement in their disability. Three patients who
made a Grade 2 response were totally incapacitated before treatment. Case 1 was
unable to turn over in bed and had to be fed. Cases 3 and 8 were severely crippled
and unable to get out of bed unaided. After six months Case 1 was back at work
as a foreman in the shipyard; Case 3 was undertaking some household duties and
had taken a bus ride to visit her family doctor for the first time for several years;
and Case 8 was able to walk a hundred yards and could ride a bicycle once more.
In lesser degrees the improvement in strength, general well-being, cheerfulness,
and freedom from pain in the other patients was most gratifying. In addition to
57the general clinical assessment already described, specific measurement of various
joint functions was carried out, details of which are to be found in Tables 4, 5,
6, 7, and 8.
Strength of Grip.
A considerable increase in strength was recorded in seven patients at the end
of one month. In three others the increase was slight, while in one there was no
change. When the average of all the patients is taken, the greatest improvement
was observed at the end of the first month, after which there was a gradual, but
definite, decline at each of the subsequent examinations. Of the four patients
(2, 4, 5, and 8), who at twelve months showed a loss of strength in comparison
with the findings at one month, three (4, 5, and 8) had the poorest clinical response
to treatment. On the whole, improvement in the strength of hand grip correlated
well with the patient's therapeutic response.
TABLE 6.
CASE No.
NIEASUREMENT OF JOINT NIOBILITY TO SHOW INCREASE (+)
OR DECREASE (-) IN MOVEMENT COMPARED WITI
INITIAL READING-(each 50 one point).
Grade of therapeutic
Joints 1 month 3 months 6 months 12 months response
Measured at 12 months
1.
2.
3.
G. R.
M. G.
M. S.
4. T. R.
5. B. I.
6. W.A.L.S.
7. G.T.
8. R.J.McV.
10. L. B.
11. J. M.
Average all
Patients
Elbows... + 16... + 18... + 20... +14...
Elbows + 4 + 5 + 3. + 5
Wrists ... + 12 ... + 10 .. + 11 ... +12
Elbows
Knees
Wrists ... + 14 ... + 2 ... + 8 ... -11
Knees
Wrists ..+11 + 7 + 2 + 8.
Elbows
Knees
Wrists ..±+1 + 8 -2...+ 3.
Elbows
Knees
Wrists ... + 11 ... 4 4 ... + 16 ... +16
Elbows
Knees
Ankles
Knees ...+ 3 + 2 + 1 +1I
Knees ... - .. + 12 + 9 +17
Knees ...+ 1.. + 3 ... 0 ... 0.
+8.2 .. +7.1 ... +6.8 ... +6.5
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2
4
3
2
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2
2Proximal Interphalangeal Joints.
At one month finger-joint swelling had diminished in all by 19 to 5.5 per cent.
The average decrease in joint size fell during the twelve months from an initial
reduction of 11.6 per cent. to 6;5 per cent. When the figures at twelve months
are compared with those at one month, five patients (1, 4, 5, 8, 9) show an actual
increase in joint size varying from 6.5 per cent. (Case 1) to 15.8 per cent. (Case 4).
Three of these (4, 5, 8) had a poor therapeutic response, whereas two (1, 9) were
classed as showing major improvement.
CASE No.
TABLE 7.
CIRCUMFERENCE OF KNEE-JOINT TO SIIOW INCREASE (+)
OR DECREASE (-) IN SIZE
(each 0.5 cm. decrease (-) two points).
Before treatment Grade of therapeutic
measurement 1 month 3 months 6 months 12 months response
both joints in cms. at 12 months
1. G.R.
2. M.G.
3. M. S.
4. T. R.
5. B. I.
6. W. A. L. S. .
7. G. T.
8. R. J. McV. .
9. D. B.
10. L. B.
11. J. M.
Overall Decrease
or Increase all
Patients
73.0
87.7
62.0
74.2
81.5
73.0
79.0
66.0
71.8
77.2
67.2
-10
-22
- 8
- 8
+9
- 3
- 6
0
-12
+ 2
- 2
- 18
- 20
+ 6
- 2
0
0
- 8
+ 4
+10
+ 2
+10
... -60 ... -16 ...
- 1
-16
- 14
- 4
+ 5
+ 2
-10
+10
+26
- 1
+10
+ 5
-18
+13
- 9
- 6
+ 2
- 4
+10
+18
+ 1
+10
+ 9 ... +20...
Joint Mobility.
This increased in all patients assessed at one month, but thereafter individual
patients varied, some gaining further increases while others showed a reduction.
The average improvement for all patients, however, declined slightly over the
twelve months of observation. The most pronounced deterioration took place in
Case No. 4, but when the individual figures for the other patients are studied there
is little variation between the assessments at one and twelve months.
Knee-joint Circumference.
The majority of patients, except Cases 5 and 10, showed a decrease in knee-joint
circumference at one month, but at three months only four (1, 2, 4, 7) had a
reduction in swelling. The overall improvement for all patients observed at one
month was thus converted into an overall increase in joint size at nine and twelve
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2months, which may be a reflection of the additional strain imposed on these joints
by the patients' greater mobility and activity. It is of interest that Case 4 and
Case 5, both of whom showed a poor therapeutic response to treatment, had a
reduction in knee-joint circumference at twelve months. It is difficult to explain
this finding, but it may, in part, be related to increase in rheumatoid activity
reducing functional use of the joint and thereby limiting swelling.
The Erythrocyte Sedimentation Rate.
The E.S.R. was 15 mm. in one hour or more in nine patients before the trial
started. Of the two with a normal E.S.R., one (Case 2) was receiving a daily
suppressive dose of 67.5 mg. of cortisone acetate, when the reading was made.
TABLE 8.
ERYTHROCYTE SEDIMENTATION RATE
Grade of therapeutic
CASE No. Before 1 month 3 months 6 months 12 months response
treatment at 12 months
1. G. R. ... 94; ... 24 ... 37 ... 10 ... 61 ... 2
2. M. G. ... 14 ... 35 ... - ... 39 ... 37 ... 2
3. M. S. ... 25 .. 6 ... - ... 9 ... 15 ... 2
4. T. R. ... 95... 33 ... 64 ... 44 ... 58 ... 4
5. B. I. ... 31 ... 22 ... - ... 40 ... 16 ... 3
6. W.A. L.S. ... 20.. 5 ... 4 ... 13 ... 10 ... 2
7. G. T. ... 28... 10 ... - .. 8 ... 9 ... 9
8.R. J. McV. ... 77 ... 3 ... 14 ... 34 ... 27 ... 3
9. D. B. ... 9 ... 3 ... 3 ... 3 ... 6 ... 2
10. L. B. ... 65 ... 2 ... 18 ... 20 ... 17 ... 2
II. J. M. .. 15 ... ... 3 ... 14 ... 12 ... 2
Average all
Patients ... 44 ... 14.3 ... 20.4 ... 21.2 ... 24.3 ...
The most marked fall in the E.S.R. was seen at one month, but thereafter the
average rose during the remainder of the trial from 14.3 mm. in one hour to
24.3 mm.
SIDE-EFFECTS OF PREDNISOLONE TREATMENT.
With the exception of the occurrence of peptic ulceration in one patient which
is described in detail below, unpleasant side-effects of prednisolone therapy were
slight and consisted of relatively trivial symptoms which the patients readily
accepted in exchange for the benefits achieved by treatment (Table 9). Rounding
of the face was seen in all, and was usually apparent within two-three months of
starting prednisolone. Although less pronounced, it assumed the characteristic
configuration seen in Cushing's Syndrome, and seemed to occur more easily with
prednisolone than in those who were previously treated with cortisone. Four
female patients (3, 5, 9, and 10) had facial flushing in addition to the "Cushingoid"
60facies, which resembled the flushes associated with the menopause, but there was
the additional complaint of a constantly hot and burning sensation. In one patient
this was a troublesome feature for some months until it ceased spontaneously.
It is unlikely that this symptom is related to secondary ovarian depression induced
by prednisolone since Case 9 became pregnant while receiving the drug and
Case 5 had had a normal menopause ten years before. It is probably the result
of a direct vasomotor response induced by the drug. An increase in facial hair
growth was observed in one patient (Case 5); it was of fine texture and caused -no
special complaint. A gain in weight was recorded in nine patients, ranging from
20 lb. to 3. lb. One patient lost 12 lb. on a restricted carbohydrate diet, while
the weight of the other patient remained unchanged. Four patients were seriously
underweight before treatment started and regained their normal weight, but in
TABLE 9.
SIDE-EFFECTS OF No. OF
PREDNISOLONE TREATMENT PATIENTS
Facial rounding . 11
Facial flushing 4
Increased facial hair growth - - - 1
Excessive gain in weight - - - 5
Dyspepsia-negative X-ray - - 2
Peptic ulcer - - - - - 1
five there was an excessive increase which represents a disadvantage of prednisolone
therapy especially in a condition such as rheumatoid arthritis. The increased
appetite induced by treatment, coupled with the metabolic effects of steroid
therapy, while advantageous in wasted patients, must be carefully observed in
those whose weights are normal, and excessive gains checked. No alterationrs in
electrolyte or water metabolism were seen during the period of observation and
no patiept had glycosuria, hypertension or mental disturbances as the result of
treatmnent.
Dyspepsia and Peptic Ulceration.
Hitherto the most serious complications of prednisolone therapy has been the
occurrence of peptic ulceration. Bollet, Black, and Bunim (1955) observed a peptic
ulcer in three out of eighteen cases treated with prednisone and prednisolone,
and stated that there was no apparent relationship between the duration of
treatment or total dose of the drug and the appearance of the ulcer. With this
danger in view, all patients had a preliminary barium meal examination of the
stomach and duodenum before starting treatment, and at intervals throughout the
trial, and, with the exception of Case No. 1, no ulceration was observed. As a
precautionary measure, however, patients were advised to take a modified peptic
ulcer type diet, an antacid tablet between meals, and the prednisolone after food.
During treatment two patients developed mild dyspepsia, but without X-ray
evidence of peptic ulceration, and the symptoms subsided rapidly without additional
therapy or alteration in prednisolone dosage.
61In Case 1 treatment was inadvertently started thirty-six hours before the result
of the barium meal examination was received in the ward. This radiograph showed
the appearance of a moderate-sized ulcer crater on the posterior wall of the body
of the stomach. The decision to continue prednisolone therapy was made, in spite
of the risk involved, because of the severity of the arthritis, and because it was
felt that the withdrawal of prednisolone in the early stage of clinical remission
would have provided a severe blow to his morale. Strict anti-ulcer treatment was
therefore given in addition to the prednisolone and a special watch kept on his
clinical condition. One month later gastroscopy was performeed bv Professor
H. W. Rodgers, who reported that there was no evidence, direct or indirect, of
a gastric ulcer, in the area, in which a typical ulcer showed on the X-ray. A
depression in the mucosa, without converging folds, wvas seen to be surrounded
by a low wall of folded mucosa which might have accounted for the radiological
appearances. 'rreatment was therefore continuedl with greater confidence, but in
February, 1956, five months after treatment started, a routine barium meal revealed
the presence of a symptomless duodenal ulcer. After two weeks in.patient treatment
there was radiological evidence of healing and no further dyspepsia or peptic
ulceration was observed during the remainder of the trial.
DISCUSSION.
The results achieved during the trial clearly demonstrate that prednisolone is
an effective suppressive agent for the treatment of rheumatoid arthritis. This was
particularly evident in those patients who had previous treatment with cortisone,
for it appeared that prednisolone possessed the advantage of re-establishing control
of symptoms in those who were no longer responding adequately to cortisone.
Two patients had greater relief of symptoms wvith 12.5 and 10 mg. of prednisolone
when 67.5 and 50 mg. of cortisone respectively had been inadequate, and the
three patients who had experience of both drugs were convinced of the superior
results achieved with prednisolone. The improvement observed in strength and
functional activity and freedom from pain has alreadv been mentioned, and this
was matched by objective evidence of increased joint function. Although complete
suppression of rheumatoid activity was not aimed at, the majority of patients made
a Grade 2 response to treatment, and this probably represents the best that can
be achieved by any drug which is not curative.
TIhe action of prednisolone is comparable with cortisone, and while its initial
results may appear superior, evidence of its diminishing activity during the trial
was obtained, which shows it possesses the same disadvantage of waning anti-
rheumatik activity previously experienced with cortisone. This was apparent in
the reactivation of the arthritic process which occurred in five patients, in three
of whom additional amounts of prednisolone were required to maintain control
thereafter. A similar finding was reported by Boland (1956).
Adverse reactions to prednisolone were, with the exception of peptic ulceration
in one patient, mild and did not interfere with treatment. While facial rounding
and flushing seem to occur more readily with prednisolone than with cortisone,
the absence of hypertension and water and electrolyte disturbances is an advantage
62which the newer steroids possess over cortisone and hydrocortisone. The occurrence
of dyspepsia and peptic ulceration in patients receiving prednisolone had already
been referred to, and from evidence available this complication warrants special
attention. Boland (1956) reported dyspepsia occurring in five patients, two of
whom had duodenal ulcers, in a series of thirty-two patients treated with
prednisolone for periods up to nine months. In a further seventy patients
changed to prednisolone after prolonged hydrocortisone treatment the incidence
of dyspepsia and ulceration increased from 7 per cent. to 37 per cent. In this
series one patient developed a duodenal ulcer during treatment, and satisfactory
healing was achieved with no alteration of prednisolone therapy. The fact that the
ulcer can be symptomless is an additional hazard and emphasises the importance of
supplementing steroid therapy with a modified peptic ulcer diet, antacids, and
the post-prandial administration of the drug in an endeavour to avoid this
complication. Whether these measures are useful in preventing haemorrhage or
perforation is uncertain, but they certainly did not prevent the occurrence of
ulceration in this patient. As pointed out in a recent leading article in the British
Medical Journal, a controlled trial to assess the value of antacids in preventing
gastro-duodenal complications is urgently needed.
Prednisolone, like cortisone, suppresses endogenous adreno-cortical activity
(Nabarro, Stewart and Walker, 1955), so that it must be remembered that abrupt
termination of treatmwt will result in symptoms of adrenal insufficiency and
patients should be warned of this danger and have an adequate supply of the drug
if they leave home. The importance, too, of temporarily increasing the dose during
a complicating illness or operation needs stressing. If treatment has to be stopped
it should be done gradually and the adrenal cortex stimulated by corticotrophin
which should overlap the final doses of prednisolone.
The knowledge that prednisolone is effective in suppressing the activity of
rheumatoid arthritis focuses attention on the selection of patients who are suitable
for treatment. This potent drug is unnecessary when the disease is mild and
responding to other well-tried measures. However, for those whose disease is
progressive so that severe crippling seems to be the likely end result, it appears
justifiable to use prednisolone in the hope that a remission may occur before
irreversible joint damage takes place. Those most likely to benefit are in the
younger and middle-age groups With severe disease of relatively recent onset and
where the disease is progressive and uninfluenced by standard methods of
treatment. Even in long-standing cases, however, considerable benefit may be
obtained, as shown by some of the patients in this series. When the decision to
undertake treatment is made the patient must be made aware of the limitations
of therapy and the necessity of carrying out strictly the measures adopted for
his safety.
SUMMARY.
A clinical trial in which eleven patients were treated with prednisolone for one
year is described. Measurement of joint function was made before treatment
started and at one, three, six, and twelve months thereafter, and the results
recorded. Improvement was most marked at one and three months, following
63which a gradual deterioration took place. Nine patients showed a Grade 2 or
major therapeutic response to treatment at six months, and eight remained in this
category at twelve months. The occurrence of peptic ulceration in one patient,
which, however, healed without alteration in the dose of prednisolone, was the
only serious complication. Minor undesirable side-effects, consisting of facial
rounding in all eleven patients, facial flushing in four, increased hair growth in
one and excessive gain in weight in five, were observed, but did not interfere with
treatment.
It is concluded that prednisone and prednisolone are effective suppressive agents
in rheumatoid arthritis, and can be used beneficially for long periods in suitable
patients. Both drugs possess one of the inherent defects of cortisone and hydro-
cortisone, and reveal in some cases a gradual decline in anti-rheumatic activity
when treatment has continued for a number of months. Because these drugs
appear to increase the incidence of dyspepsia and peptic ulceration, special measures
designed to limit these complications should be taken routinely during their
administration.
My thanks are due to Professor H. W. Rodgers, O.B.E., F.R.C.S., for the gastroscopic
examination of Case 1. Initial supplies of prednisolone were provided by Dr. A. M. Brunton
of Pfizer Ltd., and Mr. R. G. Kenny of Upjohn of England Ltd., and it is a pleasure to
record my appreciation of their assistance.
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